Fly News Breaks for August 16, 2019
Aug 16, 2019 | 08:40 EDT
As previously reported, Chardan analyst Gbolahan Amusa upgraded Solid Biosciences (SLDB) to Buy from Neutral after the company provided an update on the IGNITE DMD phase I/II study of its AAV-based gene therapy, SGT-001, for Duchenne muscular dystrophy. The company's update and trial protocol changes suggest to the analyst that concerns on SGT-001 may be addressable, which may mean Solid is still positioned to address potential manufacturing constraints in the AAV-based gene therapy DMD space. Amusa noted that Sarepta Therapeutics (SRPT) utilizes less-scalable adherent processes that may limit supply and may mean Sarepta's product could cost more per patient to manufacture. Amusa raised the price target on Solid shares to $10 from $7.50.
News For SLDB;SRPT From the Last 2 Days
There are no results for your query SLDB;SRPT